News & Updates

In patients with intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), intravesical chemohyperthermia (CHT) does not translate to better cancer control than standard room-temperature chemotherapy, according to a recent phase II study HIVEC-II.

A recent first-in-human study has shown that directly applying pembrolizumab to the bladder is a safe and effective treatment option for patients with nonmuscle-invasive bladder cancer (NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG) treatment.

Among women with stress urinary incontinence, the retropubic tension-free vaginal tape (TVT) retains its efficacy up to 24 years after initial placement, with adverse effects being uncommon and having a low impact on quality of life, according to a study.

Adding androgen receptor signaling inhibitors (ARSI) to a treatment regimen consisting of docetaxel and androgen deprivation therapy (ADT) can lead to better survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to a recent meta-analysis.

UGN-102, a nonsurgical, chemoablative gel used as a primary treatment for nonmuscle-invasive bladder cancer (NMIBC), is more patient-centred than standard treatments, according to a recent study.

Taking multivitamins regularly or for a long duration neither heightens nor reduces the risk of overall or aggressive prostate cancer among older, generally well-nourished men, results of a study have shown.